# Clinical Trials Data EGFR - Document 71

# Safety and Efficacy Study of Icotinib With Intensity-modulated Radiotherapy in Nasopharyngeal Carcinoma

## Clinical Trial: https://clinicaltrials.gov/study/NCT01534585

"eligibilityCriteria": "Inclusion Criteria:\n\n1. Patients with histological proof of squamous carcinoma of the nasopharynx.\n2. Patients must have ECOG Performance Status of 0-1.\n3. Patients should have adequate bone marrow function defined as an absolute peripheral granulocyte count (AGC) of \\>/= 1500 cells/mm3, platelet count of \\>/= 100,000 cells/mm3; adequate hepatic function with bilirubin \\</= 1.5mg/dl, AST and ALT \\</= 2x the upper limit of normal; serum creatinine \\</= 1.5mg/dl, creatinine clearance \\>/= 50 ml/min and INR 0.8 - 1.2.\n4. Patients must sign a study specific informed consent form prior to study entry.\n\nExclusion Criteria:\n\n1. Evidence of metastases by clinical or radiographic examinations.\n2. History of malignancy other than non-melanoma skin cancer.\n3. Prior chemotherapy or anticancer biologic therapy for any type of cancer, or prior radiotherapy to the head and neck region except for radioactive iodine therapy.\n4. Patients with uncontrolled intercurrent disease.\n5. Patients with currently active malignancy.\n6. Pregnant or lactating women Female patients of childbearing potential who are unwilling to practice adequate contraception during study treatment and for two months after the last administration of study drug.",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a EGFR gene mutation be eligible for the clinical trial?

Answer:  
This trial is specifically for \*\*squamous carcinoma of the nasopharynx\*\*. Having an EGFR mutation does \*not\* automatically qualify or disqualify someone. The patient would need to have this specific type of nasopharyngeal cancer to be considered. The EGFR mutation might be relevant to other trials, but is not mentioned in the inclusion or exclusion criteria for this one.